{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T20:10:04Z","timestamp":1752264604529,"version":"3.41.2"},"reference-count":24,"publisher":"ALUNA","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>Aim: To study the respiratory symptoms and respiratory functions markers in patients with irritable bowel syndrome (IBS).\nMaterials and Methods: The study included 40 patients with IBS, and 30 apparently healthy subjects. Pulmonary functions are performed using spirometry, including forced expiratory volume, forced vital capacity, Forced Expiratory Volume\/Forced Vital Capacity, peak expiratory flow rate. Classification of Irritable Bowel Syndrome subtypes performed according to the Rome III criteria.\nResults: Respiratory symptom among patients with IBS was sputum in the most common 67.5%, cough 50%, and wheeze 30% and dyspnea 37.5%. The results of the current study also revealed a significant decrease in most markers of respiratory functions markers, these include: Forced Vital Capacity which was (2.59\u00b10.12 L) in Irritable Bowel Syndrome patients as compared to healthy control group (2.82\u00b10.06 L). A significant decrease in Forced Expiratory Volume was also recorded in patients (2.18\u00b10.12 L) comparing to control subjects (2.42\u00b10.73 L). Accordingly, the Forced Expiratory Volume\/Forced Vital Capacity was also significantly decreased in patients 83.98%\u00b11.21% in comparison to healthy individuals 85.85%\u00b11.35%.\nConclusions: It was concluded that patients with irritable bowel syndrome exhibited a marked decreased in respiratory functions. It also seems that constipation is one of the underlining mechanisms for deterioration in the pulmonary functions and appearance of respiratory symptoms.<\/jats:p>","DOI":"10.36740\/merkur202503108","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T19:45:13Z","timestamp":1752263113000},"page":"347-351","source":"Crossref","is-referenced-by-count":0,"title":["Respiratory dysfunction in patients with irritable bowel syndrome"],"prefix":"10.36740","volume":"53","author":[{"given":"Hadeel S.","family":"Hadi","sequence":"first","affiliation":[{"name":"COLLEGE OF SCIENCE, UNIVERSITY OF AL-QADISIYAH, AL-QADISIYAH, IRAQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa Ali","family":"Hadi","sequence":"additional","affiliation":[{"name":"NATIONAL DIABETES CENTER, MUSTANSIRIYAH UNIVERSITY, BAGHDAD, IRAQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leqaa Ahmed","family":"Aljuranii","sequence":"additional","affiliation":[{"name":"COLLEGE OF PHARMACY, ALZAHRAA UNIVERSITY, KARBALA, IRAQ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali A.","family":"Al-fahham","sequence":"additional","affiliation":[{"name":"FACULTY OF NURSING, UNIVERSITY OF KUFA, KUFA, IRAQ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22436","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Cashman M, Martin Daniel K, Dhillon S, Puli S. Irritable Bowel Syndrome: A Clinical Review. Current rheumatology reviews. 2016;12(1):13-26. doi:10.2174\/1573397112666151231110521.","DOI":"10.2174\/1573397112666151231110521"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Roussos A, Koursarakos P, Patsopoulos D et al. Increased prevalence of irritable bowel syndrome in patients with bronchial asthma. Respir Med. 2003;97:75-9. doi: 10.1053\/rmed.2001.1409.","DOI":"10.1053\/rmed.2001.1409"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Enaud R, Prevel R, Ciarlo E et al. The Gut-Lung Axis in Health and Respiratory Diseases: A Place for Inter-Organ and Inter-Kingdom Crosstalks. Frontiers in Cellular and Infection Microbiology. 2020. doi: 10.3389\/fcimb.2020.00009.","DOI":"10.3389\/fcimb.2020.00009"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Sivagnanam P, Koutsoumpas A, Forbes A. Respiratory symptoms in patients with inflammatory bowel disease and the impact of dietary salicylates. Dig Liver Dis. 2007;39(3):232-239. doi:10.1016\/j.dld.2006.08.001.","DOI":"10.1016\/j.dld.2006.08.001"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Yao X, Yang YS, Cui LH et al. Subtypes of irritable bowel syndrome on Rome III criteria: a multicenter study. Journal of gastroenterology and Hepatology. 2012;27(4):760-765. doi: 10.1111\/j.1440-1746.2011.06930.x.","DOI":"10.1111\/j.1440-1746.2011.06930.x"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Agusti A, Hogg J. Update on the Pathogenesis of Chronic Obstructive Pulmonary Disease. The New England journal of medicine. 2019;381(13):1248-1256. doi: 10.1056\/NEJMra1900475.","DOI":"10.1056\/nejmra1900475"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Hert M, Correll C, Bobes J et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011. doi: 10.1002\/j.2051-5545.2011.tb00014.x.","DOI":"10.1002\/j.2051-5545.2011.tb00014.x"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Bohn L, Storsrud S, Liljebo Th et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial.. Gastroenterology. 2015;149(6):1399-1407.e2. doi: 10.1053\/j.gastro.2015.07.054.","DOI":"10.1053\/j.gastro.2015.07.054"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Halmos E, Power VA, Shepherd S et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67-75.e5. doi: 10.1053\/j.gastro.2013.09.046.","DOI":"10.1053\/j.gastro.2013.09.046"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Bohn L, Storsrud S, Tornblom H et al. Self-Reported Food-Related Gastrointestinal Symptoms in IBS Are Common and Associated With More Severe Symptoms and Reduced Quality of Life. The American Journal of Gastroenterology. 2013;108:634-641. doi: 10.1038\/ajg.2013.105.","DOI":"10.1038\/ajg.2013.105"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Ong DK, Shaylyn MB, Shepherd BJ et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol. 2010;25(8):1366-73. doi: 10.1111\/j.1440-1746.2010.06370.x.","DOI":"10.1111\/j.1440-1746.2010.06370.x"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Staudacher H, Lomer M, Farquharson F et al. A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial. Gastroenterol. 2017;153(4):936-947. doi:10.1053\/j.gastro.2017.06.010.","DOI":"10.1053\/j.gastro.2017.06.010"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13. Wouters M, Dafne B, Wanrooy S et al. Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome. Gastroenterol. 2016;150(4):875-87.e9. doi:10.1053\/j.gastro.2015.12.034.","DOI":"10.1053\/j.gastro.2015.12.034"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Major G, Pritchard S, Murray K et al. Colon Hypersensitivity to Distension, Rather Than Excessive Gas Production, Produces Carbohydrate-Related Symptoms in Individuals With Irritable Bowel Syndrome. Gastroenterol. 2017;152(1):124-133.e2. doi:10.1053\/j.gastro.2016.09.062.","DOI":"10.1053\/j.gastro.2016.09.062"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Tojo R, Suarez Adolfo, Clemente M et al. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis.. World J gastroenterol. 2014;20(41):15163-76. doi:10.3748\/wjg.v20.i41.15163.","DOI":"10.3748\/wjg.v20.i41.15163"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Vich VA, Imhann F, Collij V et al. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Sci Transl Med. 2018;10(472):eaap8914. doi: 10.1126\/scitranslmed.aap8914.","DOI":"10.3410\/f.734657732.793557155"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Eswaran S, Chey W, Han-Markey T et al. A randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D. Am J Gastroenterol. 2016;111:1824-1832. doi:10.1038\/ajg.2016.434.","DOI":"10.1038\/ajg.2016.434"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Mcintosh K, Reed D, Theresa S et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomized controlled trial. Gut. 2016;66:1241-1251. doi:10.1136\/gutjnl-2015-311339.","DOI":"10.1136\/gutjnl-2015-311339"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Palma GDe, Lynch M, Jun L et al. Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. Sci Transl Med. 2017;9(379):eaaf6397. doi:10.1126\/scitranslmed.aaf6397.","DOI":"10.3410\/f.727365371.793533515"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Casen C, Vebo H, Sekelja M et al. Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Alimentary Pharmacology & Therapeutics. 2015;42:71-83. doi:10.1111\/apt.13236.","DOI":"10.1111\/apt.13236"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Banu K-S, Chowdhury B. Forced vital capacity in idiopathic pulmonary fibrosis-FDA review of pirfenidone and nintedanib. N Engl J Med. 2015;372(13):1189-91. doi: 10.1056\/NEJMp1500526.","DOI":"10.1056\/nejmp1500526"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Johannesson E, Simren M, Strid H et al. Physical Activity Improves Symptoms in Irritable Bowel Syndrome: A Randomized Controlled Trial. Am J Gastroenterol. 2011;106:915-922. doi: 10.1038\/ajg.2010.480.","DOI":"10.1038\/ajg.2010.480"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Raghu G, Blink B, Hamblin M et al. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial. JAMA. 2018;319:2299-2307. doi: 10.1001\/jama.2018.6129.","DOI":"10.1001\/jama.2018.6129"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Yiying H, Cuiyan T, Jian W et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir Res. 2020;21(1):163. doi: 10.1186\/s12931-020-01429-6.","DOI":"10.1186\/s12931-020-01429-6"}],"container-title":["Polski Merkuriusz Lekarski"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T19:45:15Z","timestamp":1752263115000},"score":1,"resource":{"primary":{"URL":"https:\/\/polskimerkuriuszlekarski.pl\/wp-content\/uploads\/library\/PolMerkurLek2025i3.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025,6]]}},"URL":"https:\/\/doi.org\/10.36740\/merkur202503108","archive":["Internet Archive"],"relation":{},"ISSN":["1426-9686"],"issn-type":[{"value":"1426-9686","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}